Therefore, though the expression of CD28+ T cells remains at a normal level, the decreased level of CD86+ DCs and the unbalanced ratio of CD80/CD86 may also prevent the activation of T cells in DN-CML patients. This evidence concerns the gene CD28 and chronic myelogenous leukemia, BCR-ABL1 positive.